Jubilant Pharmova Unit Gets Tentative USFDA Nod for Pantoprazole Sodium DR

Jubilant Generics Limited, a subsidiary of Jubilant Pharma Limited, has received tentative approval from the USFDA for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet. This follows a pre-approval inspection (PAI) at the Roorkee facility. The approval is contingent upon the expiry of the relevant patent, anticipated in December 2026, after which final approval is expected. This development signifies progress in the company's generic drug pipeline and its ability to secure US regulatory approvals.